Mammary tumor development in MMTV-c-myc/MMTV-v-HA-ras transgenic mice is unaffected by osteopontin deficiency

Breast Cancer Research and Treatment

Volumn 63, Issue 1, 2000, Pages 71-79

  Feng, F ^a   Rittling, S R ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Gene knockout; Mammary; Osteopontin; Ras; Transgenic; Tumorigenesis

Indexed keywords

OSTEOPONTIN; SIALOPROTEIN; VITRONECTIN;

ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INCIDENCE; DISEASE ASSOCIATION; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GROWTH RATE; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, RAS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; RECEPTORS, VIRUS; SIALOGLYCOPROTEINS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033784156     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006466516192     Document Type: Article

References (50)

1. Osteopontin expression and function: Role in bone remodeling
2. 1 integrin
3. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin
4. Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment
5. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins
6. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis
7. Receptor-ligand interaction between CD44 and osteopontin (ETA-1)
8. Osteopontin
9. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro
10. Altered wound healing in mice lacking a functional osteopontin gene (spp1)
11. Osteopontin (OPN) function in pathology: Lessons from OPN-deficient mice
12. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation
13. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation
14. Induction of expression of osteopontin (OPN, secreted phosphoprotein) in metastatic, ras-transformed NIH-3T3 cells
15. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell
16. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines
17. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA
18. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts
19. Expression of antisense osteopontin mRNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells
20. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression
21. Enhanced expression of the osteopontin gene in metastatic rat mammary epithelial-drived cell lines
22. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line
23. Promotion of angiogenesis and enhancement of breast cancer metastasis to bone
24. Osteopontin expression in mammary gland development and tumorigenesis
25. Osteopontin expression and distribution in human carcinomas
26. The LCC-15 MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype
27. Osteopontin expression in a group of lymph node negative breast cancer patients
28. Coexpression of MMTV/v-Ha-ras and MMTV-c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo
29. Animal models of human disease
30. Murine bone sialoprotein (BSP): cDNA cloning, mRNA expression and genetic mapping
31. Detection of mouse osteopontin by western blotting
32. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro
33. F4/80, a monoclonal antibody directed specifically against the mouse macrophage
34. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo
35. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo
36. Human bone sialoprotein. Deduced protein sequence and chromosomal localization
37. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels
38. Tumor cells are the source of osteopontin and bone sialo-protein expression in human breast cancer
39. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin
40. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo
41. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer
42. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene
43. Integrins: Versatility, modulation, and signaling in cell adhesion
44. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
45. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions
46. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors
47. Mapping of the human and mouse bone sialoprotein and osteopontin loci
48. Expression of bone sialoprotein (BSP) in developing human tissues
49. Vitronectin
50. Constitutive and regulated expression of vitronectin